3 stocks that could skyrocket by 2027 thanks to the development of weight loss drugs
In recent years, stocks of companies focused on the treatment of obesity and diabetes have been gaining in popularity. Given the growing health problems associated with obesity, which the COVID-19 pandemic has further accentuated, this market seems very promising. The increasing number of obese people in the world and the increased awareness about the risks associated with excessive body weight are leading to a greater demand for effective solutions.

As health systems across the globe strive to better control these chronic conditions, the importance of pharmaceutical innovation in this area continues to grow. Technological advances and improved clinical practices are further supporting the development of new, more effective drugs. The following three companies could dominate the market and offer significant opportunities for investors in the coming years.
Eli Lilly $LLY
Eli Lilly, one of the world's leading pharmaceutical companies, specializes in developing drugs for a wide range of…